Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical solution formulations for pressurised metered dose inhalers

Inactive Publication Date: 2006-11-16
CHIESI FARM SPA
View PDF22 Cites 81 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0082] A higher degree of co-deposition following the combined administration of two drugs has been found also by using a single metered dose inhaler containing salmeterol xinafoate and fluticasone propionate both in the form of solid particles suspended in the HFA propellant. Also in this case the effect has been ascribed to the formation of particle agglomerations (Intern. J. Pharmaceutics, 2006, 313, 14-22).
[0091] Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

Problems solved by technology

Asthma and chronic obstructive pulmonary disease (COPD) are the most common broncho-pulmonary diseases and represent a major public health problem.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical solution formulations for pressurised metered dose inhalers
  • Pharmaceutical solution formulations for pressurised metered dose inhalers
  • Pharmaceutical solution formulations for pressurised metered dose inhalers

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Hydrochloric Acid on Solution pH′ (Acidity Function)

[0092] (a) 1.0 M hydrochloric acid was added incrementally to 50 ml of HFA 43-10MEE (Vertrel XF) containing 20% w / w ethanol and the pH′ was measured after each aliquot of acid. FIG. 1 shows the resultant titration curve normalised to the usual fill volume of a pMDI can (12 ml). The pH′ profile exhibits a shallow negative slope to about pH′=5.5; thereafter the acidity function drops abruptly.

[0093] (b) Experiment (a) was repeated with formoterol formulations containing a lower concentration of ethanol (12% w / w) and with the addition of 1.0% isopropyl myristate. The resultant pH profile, for replicate bulk solutions, shown in FIG. 2 is similar in shape with the abrupt fall in pH′ per unit increment of acid again commencing at about pH′=5.5. However, only about half the acid is required to achieve the same reduction in pH′. This is largely due to the reduction in ethanol content; FIG. 2 also shows similarity in the profile...

example 2

Effect of pH′ on Stability of Formoterol Solutions in HFA 43-10MEE containing 20% w / w Ethanol

[0094] Aliquots of 1.0 M hydrochloric acid were added to 12 ml of formoterol solution in glass vials. After measurement of pH, valves were crimped on and the vials stored upright at 50° C. Vial samples containing different concentrations of acid were assayed for residual formoterol after 10 and 20 days storage. The pH′ of a third vial was determined after 40 days storage. The results are shown in Table 1. Table 1 shows changes in pH on storage; this is probably largely associated with leaching of alkali from the soft glass of the vials. However, overall consideration of the pH′ and formoterol content data implies that the stability of a solution formulation of the drug in HFA can be improved by the addition of mineral acid to provide a formulation with pH′ between 2.5 to 5.0.

TABLE 1pH′ and Formoterol Content of Formoterol-Vertrel XF / HFA Solutions(12 μg / 100 μl)Vehicle: Vertrel XF / HFA with ...

example 3

Stability of Acidified Formoterol-HFA 134a Solutions in Anodised Cans

[0095] Formoterol formulations (12 μg / 100 μl) were prepared by dissolving 1.44 mg of formoterol fumarate in HFA 134a containing 12% w / w ethanol with and without 1.0% w / w isopropyl myristate. The latter was included as a non-volatile excipient with the potential for increasing MMAD if so desired. It also improves the solubility of formoterol in the vehicle and reduces polarity of the vehicle compared to the addition of glycerol.

[0096] pMDI cans containing 3.1 to 3.4 μl 1.0 M hydrochloric acid were set down on storage, upright and inverted, at 4° C. to 50° C. and samples taken for analysis of formoterol content at appropriate intervals.

[0097] Stability data obtained after 70 days of storage are given in Table 2.

[0098] A matrix of formulations containing 1.44 mg (12 μg / 100 μl) formoterol fumarate were prepared in HFA 134a containing 12.0% w / w ethanol with or without 1.0% w / w isopropyl myristate as non-volatile exc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to View More

Abstract

A method for delivering two or more active drug substances to the lungs by inhalation from a single pressurized metered dose inhaler product, said inhaler containing a HFA / cosolvent based solution formulation wherein all the active drug substances are fully dissolved in the formulation.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The invention relates to pharmaceutical solution to be used with pressurised metered dose inhalers (pMDIs) suitable for aerosol administration. In particular, the invention relates to aerosol solution formulations to be used with pressurised metered dose inhalers (pMDIs), suitable for the administration of a medicament to the lungs, said medicament comprising two or more active drug substances. More particularly, the invention relates to a method for delivering two or more active drug substances to the lungs by inhalation from a single inhaler. In a preferred embodiment one of the drug substances is a long-acting β2-agonist. [0003] 2. Discussion of the Background [0004] Treatment of pulmonary disease with inhaled aerosol drugs offers advantages over systemic therapy, including a more rapid onset and reduced adverse effects, because of direct targeting of the lungs. [0005] Pressurised metered dose inhalers (pMDIs) ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61L9/04A61K31/573A61K31/4745A61K31/138
CPCA61K31/4745A61K31/138A61K31/573A61K31/58A61K45/06A61K47/10A61K31/57A61K9/008A61K2300/00A61K9/08A61K31/167A61K47/06A61P11/00A61P11/06A61P43/00A61K9/124A61K31/4704
Inventor LEWIS, DAVID ANDREWMEAKIN, BRIAN JOHNBRAMBILLA, GAETANO
Owner CHIESI FARM SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com